2009 in cancer

FDA · US: 38 records / 23 drugsHealth Canada · CA: 14 records / 11 drugsEMA · EU: 8 records / 7 drugs

• Nov 5, 2009Romidepsin FDA · US original application approved Primary Cutaneous T-Cell Non-Hodgkin LymphomaISTODAX is indicated for the treatment of cutaneous T-cell lymphoma (CTCL) in adult patients who have received at least one prior systemic therapy. ISTODAX is…openfda
• Oct 19, 2009Pazopanib FDA · US original application approved Soft Tissue SarcomaLimitations of Use : The efficacy of VOTRIENT for the treatment of patients with adipocytic soft tissue sarcoma or gastrointestinal stromal tumors has not been…openfda
• Oct 19, 2009Pazopanib FDA · US original application approved Soft Tissue Sarcomaadvanced soft tissue sarcoma (STS) who have received prior chemotherapy.openfda
• Oct 19, 2009Pazopanib FDA · US original application approved Renal Cell Carcinomaadvanced renal cell carcinoma (RCC).openfda
• Sep 24, 2009Pralatrexate FDA · US original application accelerated approved Mature T-Cell and NK-Cell Non-Hodgkin LymphomaFOLOTYN is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated…openfda
• Aug 7, 2009Oxaliplatin FDA · US original application approved Malignant Colon Neoplasmadjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. ( 1 )openfda
• Aug 7, 2009Oxaliplatin FDA · US original application approved Malignant Colorectal Neoplasmtreatment of advanced colorectal cancer. ( 1 )openfda
• Aug 7, 2009Oxaliplatin FDA · US original application approved Malignant Colon Neoplasmadjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor.openfda
• Aug 7, 2009Oxaliplatin FDA · US original application approved Malignant Colorectal Neoplasmtreatment of advanced colorectal cancer. Oxaliplatin is a platinum-based drug used in combination with infusional fluorouracil and leucovorin, which is…openfda
• Jul 22, 2009Vinorelbine FDA · US original application approved Lung Non-Small Cell CarcinomaVinorelbine injection is indicated: In combination with cisplatin for first-line treatment of patients with locally advanced or metastatic non-small cell lung…openfda
• Jun 17, 2009Dexamethasone FDA · US original application approved Conventional OsteosarcomaThe treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO)openfda
• Jun 9, 2009Melphalan FDA · US original application approved Multiple MyelomaMelphalan Hydrochloride for Injection is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.openfda
• Mar 30, 2009Everolimus FDA · US original application approved Malignant Breast NeoplasmPostmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with…openfda
• Mar 30, 2009Everolimus FDA · US original application approved Renal Cell CarcinomaAdults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib.openfda
• Mar 30, 2009Everolimus FDA · US original application approved Primitive Neuroectodermal TumorAdults with progressive neuroendocrine tumors of pancreatic origin (PNET) and adults with progressive, well-differentiated, non-functional neuroendocrine…openfda
• Feb 27, 2009Temozolomide FDA · US original application approved GlioblastomaNewly diagnosed glioblastoma concomitantly with radiotherapy and then as maintenance treatment.openfda
• Feb 27, 2009Temozolomide FDA · US original application approved Anaplastic AstrocytomaTreatment of adults with refractory anaplastic astrocytoma.openfda
• Feb 27, 2009Temozolomide FDA · US original application approved Anaplastic AstrocytomaAdjuvant treatment of adults with newly diagnosed anaplastic astrocytoma.openfda
• Feb 27, 2009Temozolomide FDA · US original application approved Anaplastic AstrocytomaAnaplastic astrocytoma.openfda
• Oct 26, 2009Ofatumumab FDA · US original application approved cancer not stated in this recordKESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease,…openfda
• Jun 17, 2009Dexamethasone FDA · US original application approved cancer not stated in this recordThe treatment of non-infectious uveitis affecting the posterior segment of the eye • The treatment of diabetic macular edemaopenfda
• Jun 11, 2009Ibuprofen FDA · US original application approved cancer not stated in this recordCALDOLOR is indicated in adults and pediatric patients aged 3 months and older for the: management of mild to moderate pain, including postoperative pain…openfda
• Mar 30, 2009Everolimus FDA · US original application approved cancer not stated in this recordAdults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. • AFINITOR and AFINITOR DISPERZ are kinase inhibitors…openfda
• Sep 21, 2009Vinflunine EMA · EU centralised approved Urothelial CarcinomaJavlor is indicated in monotherapy for the treatment of adult patients with advanced or metastatic transitional-cell carcinoma of the urothelial tract after…ema
• Aug 2, 2009Everolimus EMA · EU centralised approved Renal Cell CarcinomaHormone-receptor-positive advanced breast cancer Afinitor is indicated for the treatment of hormone-receptor-positive, HER2/neu-negative advanced breast…ema
• Jun 24, 2009Gefitinib EMA · EU centralised approved Lung Non-Small Cell CarcinomaIressa is indicated for the treatment of adult patients with locally advanced or metastatic non-small-cell lung cancer with activating mutations of…ema
• Mar 6, 2009Mifamurtide EMA · EU centralised approved OsteosarcomaMepact is indicated in children, adolescents and young adults for the treatment of high-grade resectable non-metastatic osteosarcoma after macroscopically…ema
• Feb 17, 2009Degarelix EMA · EU centralised approved Malignant Prostate NeoplasmFIRMAGON is a gonadotrophin releasing hormone (GnRH) antagonist indicated: - for treatment of adult male patients with advanced hormone-dependent prostate…ema
• Dec 30, 2009Bortezomib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2009-12-30 (see label)openfda
• Dec 30, 2009Bortezomib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2009-12-30 (see label)openfda
• Nov 24, 2009Degarelix Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as FIRMAGON (DIN 02337037) under ATC L02BX02 DEGARELIX. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
• Nov 24, 2009Degarelix Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as FIRMAGON (DIN 02337029) under ATC L02BX02 DEGARELIX. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
• Oct 16, 2009Rituximab FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2009-10-16 (see label)openfda
• Sep 23, 2009Vorinostat FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2009-09-23 (see label)openfda
• Sep 14, 2009Epirubicin Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as EPIRUBICIN HYDROCHLORIDE INJECTION (DIN 02324091) under ATC L01DB03 EPIRUBICIN. Indications are not published in the Drug Product…health-canada-dpd
• Sep 3, 2009Ibritumomab Tiuxetan FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2009-09-03 (see label)openfda
• Jul 31, 2009Bevacizumab FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2009-07-31 (see label)openfda
• Jul 30, 2009Plerixafor EMA · EU centralised approved cancer not stated in this recordMozobil is indicated in combination with granulocyte-colony-stimulating factor to enhance mobilisation of haematopoietic stem cells to the peripheral blood for…ema
• Jul 2, 2009Pemetrexed FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2009-07-02 (see label)openfda
• Jun 30, 2009Sodium Iodide 131 I Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as DRAXIMAGE SODIUM IODIDE I131 CAPSULES, USP THERAPEUTIC (DIN 02329743) under ATC V10XA01 SODIUM IODIDE 131 I. Indications are not…health-canada-dpd
• Jun 30, 2009Sodium Iodide 131 I Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as DRAXIMAGE SODIUM IODIDE I131 SOLUTION, USP THERAPEUTIC (DIN 02329778) under ATC V10XA01 SODIUM IODIDE 131 I. Indications are not…health-canada-dpd
• Jun 30, 2009Cladribine Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as CLADRIBINE INJECTION (DIN 02319918) under ATC L01BB04 CLADRIBINE. Indications are not published in the Drug Product Database — see the…health-canada-dpd
• Jun 29, 2009Vorinostat Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as ZOLINZA (DIN 02327619) under ATC L01XH01 VORINOSTAT. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
• Jun 16, 2009Methyl Aminolevulinate Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as METVIX (DIN 02323273) under ATC L01XD03 METHYL AMINOLEVULINATE. Indications are not published in the Drug Product Database — see the…health-canada-dpd
• Jun 5, 2009Lapatinib Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as TYKERB (DIN 02326442) under ATC L01EH01 LAPATINIB. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
• May 29, 2009Zoledronic Acid FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2009-05-29 (see label)openfda
• May 27, 2009Imatinib Mesylate FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2009-05-27 (see label)openfda
• May 27, 2009Imatinib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2009-05-27 (see label)openfda
• May 21, 2009Dasatinib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2009-05-21 (see label)openfda
• May 14, 2009Interferon Beta-1a Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as REBIF (DIN 02318261) under ATC L03AB07 INTERFERON BETA-1A. Indications are not published in the Drug Product Database — see the Health…health-canada-dpd
• May 14, 2009Interferon Beta-1a Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as REBIF (DIN 02318253) under ATC L03AB07 INTERFERON BETA-1A. Indications are not published in the Drug Product Database — see the Health…health-canada-dpd
• May 5, 2009Bevacizumab FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2009-05-05 (see label)openfda
• May 4, 2009Dasatinib Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as SPRYCEL (DIN 02320193) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
• Apr 30, 2009Anastrozole FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2009-04-30 (see label)openfda
• Mar 20, 2009Bleomycin Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as BLEOMYCIN FOR INJECTION (DIN 02265982) under ATC L01DC01 BLEOMYCIN. Indications are not published in the Drug Product Database — see the…health-canada-dpd
• Mar 13, 2009Zoledronic Acid FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2009-03-13 (see label)openfda
• Feb 27, 2009Glatiramer FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2009-02-27 (see label)openfda
• Feb 21, 2009Temozolomide Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as TEMODAL (DIN 02312794) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
• Feb 6, 2009Filgrastim EMA · EU centralised approved cancer not stated in this recordReduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy…ema
• Feb 6, 2009Filgrastim EMA · EU centralised approved cancer not stated in this recordReduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy…ema

RegulatoryAll 2009 records with filters →

Studies

4,052

Interventional

3,192

Phase III

398

Industry-led

992

With posted results

1,191

Countries with sites

91

Published source: clinicaltrials · first_posted_date as posted